Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Andrew McConaghie

Senior Writer

Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.

He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.

Latest From Andrew McConaghie

Bavarian Nordic Rises As It Meets Demand For Monkeypox Vaccine

The Danish company has the world’s only licensed monkeypox vaccine and is now fielding enquiries from concerned governments from around the world.

Commercial Companies

Gene Therapy Development Should Involve Fewer Surprises, Says US FDA’s Marks

Regulators want to help smooth the process of bringing a gene therapy to market, hoping to iron out ‘surprises’ and even address reimbursement issues for the sake of patients.

Commercial Clinical Trials

FDA Leader: We Need To Remove Surprises From Gene Therapy Development

Embattled gene therapy companies will take comfort from desire of FDA and EMA help smooth the process of bringing the novel treatments to market.

Commercial Companies

AstraZeneca Buys Into COVID-19 Antibodies From Newly Launched RQ Bio

The big pharma company and its new partner both expect demand to continue for pre-exposure prophylaxis antibody therapies, for COVID-19 and beyond.

Deals Infectious Diseases

Sanofi's Sarclisa Scores In Myeloma But Is Still In Darzalex’s Shadow

The French company believes it has the best-in-class CD38 antibody with new PFS data, but Johnson & Johnson and Genmab’s Darzalex looks set to retain its advantage in multiple myeloma.

Companies Clinical Trials

PD-1 Knockout Could Be Caribou’s Key To Allo CAR-T Success

While it is still early days for Caribou, early signs suggest it could have the first off-the-shelf program to rival established CAR-T therapies.

Companies Commercial
See All
UsernamePublicRestriction

Register